Skip to main content
. 2021 Sep 9;19:141. doi: 10.1186/s12969-021-00619-w

Table 3.

Performance measures for the ACR 1997, SLICC 2012 and ACR/EULAR 2019 criteria according to first visit, first year and latest periods

Criteria Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI) ROC (95% CI) Accuracy (95% CI)
ACR 1997
 1st visit 49% (40–59%) 96% (87–99%) 97% (88–99%) 46% (36–56%) 0.73 (0.67–0.78) 64% (56–71%)
 1st year 57% (47–66%) 96% (87–99%) 97% (90–99%) 50% (40–60%) 0.76 (0.71–0.82) 69% (61–76%)
 Latest 66% (56–74%) 96% (87–99%) 97% (91–99%) 56% (45–66%) 0.81 (0.76–0.86) 75% (68–81%)
SLICC
 1st visit 76% (67–84%) 94% (84–99%) 97% (91–99%) 64% (52–75%) 0.85 (0.80–0.90) 82% (75–87%)
 1st year 84% (76–90%) 94% (84–99%) 97% (91–99%) 73% (60–83%) 0.89 (0.84–0.94) 87% (81–92%)
 Latest 86% (78–92%) 94% (84–99%) 97% (92–99%) 75% (63–85%) 0.90 (0.85–0.95) 88% (83–93%)
ACR/EULAR
 1st visit 81% (73–88%) 92% (81–98%) 96% (90–99%) 69% (57–80%) 0.87 (0.82–0.92) 85% (78–90%)
 1st year 88% (80–93%) 90% (79–97%) 95% (89–98%) 77% (64–87%) 0.89 (0.84–0.94) 88% (83–93%)
 Latest 89% (82–94%) 90% (79–97%) 95% (89–99%) 79% (67–89%) 0.90 (0.85–0.95) 90% (84–94%)
ACR/EULARa
 1st visit 76% (67–84%) 96% (87–99%) 98% (92–99%) 65% (53–75%) 0.86 (0.81–0.91) 83% (76–88%)
 1st year 83% (74–89%) 96% (87–99%) 98% (93–99%) 71% (59–81%) 0.89 (0.85–0.94) 87% (81–92%)
 Latest 84% (76–90%) 96% (87–99%) 98% (93–99%) 73% (61–83%) 0.90 (0.86–0.94) 88% (83–93%)

ACR/EULARa, a score of ≥13 as compared to the traditional cut of score of ≥10

The median disease duration was 5 (2.5–9) years with a range of 1–19 years

ACR American College of Rheumatology 1997, SLICC Systemic Lupus Erythematosus International Collaborating Clinics, EULAR European League Against Rheumatism, CI Confidence interval, PPV Positive predictive value, NPV Negative predictive value, ROC Area under the received operating curve